Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

The aim of this research was to differentiate dapagliflozin, empagliflozin, and canagliflozin based on their capacity to inhibit sodium‐glucose cotransporter (SGLT) 1 and 2 in patients with type 2 diabetes using a previously developed quantitative systems pharmacology model of renal glucose filtrati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokolov, Victor, Yakovleva, Tatiana, Chu, Lulu, Tang, Weifeng, Greasley, Peter J., Johansson, Susanne, Peskov, Kirill, Helmlinger, Gabriel, Boulton, David W., Penland, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180004/
https://www.ncbi.nlm.nih.gov/pubmed/32064793
http://dx.doi.org/10.1002/psp4.12498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180004/
https://www.ncbi.nlm.nih.gov/pubmed/32064793
http://dx.doi.org/10.1002/psp4.12498

Ejemplares similares